Actively Recruiting
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
Led by Mansoura University · Updated on 2025-08-20
100
Participants Needed
1
Research Sites
102 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
CONDITIONS
Official Title
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Portal vein thrombosis, cirrhosis, with or without hepatocellular carcinoma (HCC), Child A & B
You will not qualify if you...
- Platelets less than 10,000
- Creatinine greater than 1.9
- Budd-Chiari syndrome
- Uncontrolled active bleeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mansoura University Hospitals
Al Mansurah, Dakahlia Governorate, Egypt, 35511
Actively Recruiting
Research Team
D
Dalia Elsayed Ganady, MBBS
CONTACT
H
Hatem Elalfy, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here